|Selected research from leading health care experts whose findings have a direct bearing on public policies effecting medical progress. Research is chosen based on its quality and relevance by the Medical Progress Today editorial staff.||
Imatinib Manipulation Modifies Resistant Leukemia
In the January 1 issue of Cancer, researchers reported that Gleevec resistant cancer cells, which over express the gene BCR-ABL, can be killed when Gleevec treatment is actually halted. “Abrupt withdrawal of the BCR-ABL inhibitor [Gleevec] from resistant leukemia cells leads to apoptosis of these BCR-ABL overexpressing cells.”
Ironically, Gleevec resistant cells were weakened by the discontinuation of Gleevec treatment; researchers theorize that this weakness “could be exploited” to make these cells more vulnerable to other forms of treatment.
|home spotlight commentary research events news about contact links archives|